Overview
What is Semax / Selank?
Semax and Selank are synthetic neuropeptides developed by Russian research institutes. Semax is a heptapeptide analogue of ACTH(4-10) studied for cognitive function and neuroprotection. Selank is a synthetic analogue of tuftsin studied for anxiolytic and immunomodulatory properties. This combination kit provides both compounds for concurrent research into complementary neuropeptide pathways.
Semax / Selank (Semax + Selank Combination) is supplied strictly as a reference material for in vitro and preclinical investigation. All characterization data described here is drawn from peer-reviewed literature and laboratory analysis; nothing herein constitutes a claim of clinical effect in humans.
Investigational Scope
Documented Research Areas
The following domains summarize directions explored across published studies and laboratory models. Each reflects observations reported in rodent models, in vitro systems, or the peer-reviewed record.
Cognitive Research
BDNF & Neuroplasticity (Semax)
Semax has been studied for its ability to upregulate BDNF (brain-derived neurotrophic factor) expression in rodent brain tissue. Research has examined effects on learning, memory consolidation, and neuroplasticity markers.
Anxiolytic Research
Stress & Anxiety Models (Selank)
Selank has been examined in rodent anxiety models including elevated plus maze and open field tests. Studies have documented anxiolytic effects without observed sedation, alongside modulation of GABA-A receptor activity.
Immune Modulation
Immunomodulatory Biology (Selank)
As a tuftsin analogue, Selank has been studied for its immunomodulatory properties. Research has examined effects on cytokine balance, NK cell activity, and T-cell function in rodent immune models.
Neuroprotection
Ischemia & Oxidative Stress (Semax)
Research has examined Semax's neuroprotective properties in models of cerebral ischemia and oxidative stress, with documented effects on neuronal survival markers and inflammatory gene expression in brain tissue.
Proposed Mechanism
Mechanistic Pathway
Mechanistic steps below are hypothesized from in vitro assays and animal-model data reported in the literature. They describe biochemical interactions observed under controlled experimental conditions.
-
1
Semax: BDNF & TrkB Pathway
Semax stimulates BDNF expression and activates TrkB receptor signaling in hippocampal and cortical neurons, supporting synaptic plasticity and neuronal survival mechanisms documented in rodent model research.
-
2
Semax: Dopamine & Serotonin Modulation
Studies have examined Semax's effects on monoaminergic systems, with documented changes in dopamine and serotonin turnover in prefrontal cortex and hippocampus of rodent subjects.
-
3
Selank: GABA-A Receptor Modulation
Research has documented Selank's ability to modulate GABA-A receptor function, with studies showing benzodiazepine-like anxiolytic effects without receptor downregulation or dependence markers in rodent models.
-
4
Selank: Enkephalin Degradation Inhibition
Selank has been shown to inhibit enkephalin-degrading enzymes, potentially elevating endogenous opioid peptide levels in CNS tissue and contributing to observed anxiolytic and stress-modulating effects.
Technical Data
Molecular Specifications
| Amino Acid Sequence | Semax: Met-Glu-His-Phe-Pro-Gly-Pro | Selank: Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Molecular Weight | Semax: 813.9 g/mol | Selank: 751.9 g/mol |
| Molecular Formula | Semax: C₃₇H₅₁N₉O₁₀S | Selank: C₃₃H₅₇N₉O₉ |
| CAS Number | Semax: 80714-61-0 | Selank: 129954-34-3 |
| Storage | −20°C long-term, 4°C short-term up to 4 weeks |
References
Selected Literature
The following peer-reviewed references informed the research summaries on this page. Citations are provided for scientific context only.
- Sebentsova EA, et al. (2008). Semax affects multiple neuropeptide systems in the brain. Neuroscience Letters, 443(1), 1–5.
- Inozemtsev AN, et al. (2014). Selank and its synthetic analogues: anxiolytic properties. Bulletin of Experimental Biology and Medicine, 157(1), 52–54.
- Shadrina MI, et al. (2010). Neuroprotective effect of Semax in rat model of focal cerebral ischemia. Bulletin of Experimental Biology and Medicine, 148(4), 572–574.
- Seredenin SB & Voronin MV. (2009). Neuroreceptor mechanisms of anxiolytic action of selank. Eksperimental'naya i Klinicheskaya Farmakologiya, 72(4), 6–8.
- Zozulya AA, et al. (2001). Pharmacological properties of Selank: an anxiolytic peptide. Psychopharmacology, 155(2), 107–115.
Research Disclaimer
This product is intended strictly for laboratory research purposes only. It is not a drug, food, cosmetic, or dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. It is not for human or animal consumption. All information presented is derived from published scientific literature and is provided for educational reference only. By purchasing, the buyer affirms they are a qualified researcher or institution and assume full responsibility for the safe and lawful handling of this material.